← Russell 3000 cross-section

PEN Penumbra Inc

Trailing twelve months to 2026-06-30 · as filed 2026-07-30, not restated
Healthcare

Scale

Market cap
$12.7bn
Revenue TTM
$1.5bn
Net income TTM
$161m
Free cash flow
$216m
Composite score
48.7
Sector rank
#611

Valuation

P / E
79.0
EV / EBITDA
58.8
EV / sales
8.0
FCF yield
1.70%
Earnings yield vs 10-yr
-3.46pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
10.7%
EBITDA margin
13.6%
ROE
10.5%
ROIC
21.5%
Revenue growth
17.6%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Generally, when we introduce a next generation product or a new product designed to replace a current product, sales of the earlier generation product or the product replaced decline. In the three months ended June 30, 2026 and 2025, 21.7% and 23.2% of our revenue, respectively, was generated from customers located outside of the United States. In the six months ended June 30, 2026 and 2025, 21.3% and 22.0% of our revenue, respectively, was generated from customers located outside of the United States. …Penumbra Inc, 10-Q, period ended 2026-06-30, filed 2026-07-30

Read the full passage →